1. Intrapleural Fibrinolytics and Deoxyribonuclease for Treatment of Indwelling Pleural Catheter-Related Pleural Infection: A Multi-Center Observational Study
- Author
-
Sanjeevan Muruganandan, Najib M. Rahman, Y. C. Gary Lee, Juan Pablo Uribe Becerra, Deirdre B. Fitzgerald, Nick A Maskell, Liju Ahmed, Adnan Majid, Kevin G. Blyth, Hugh Ip, Rachelle Asciak, S. Tsim, and Steven Walker
- Subjects
Male ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,medicine.medical_treatment ,medicine.disease_cause ,Tissue plasminogen activator ,Leukocyte Count ,Catheters, Indwelling ,Fibrinolytic Agents ,medicine ,Humans ,Respiratory Tract Infections ,Empyema, Pleural ,Aged ,Deoxyribonucleases ,business.industry ,Deoxyribonuclease ,Middle Aged ,Pleural Diseases ,medicine.disease ,Empyema ,Surgery ,Pleural Effusion ,Cardiothoracic surgery ,Staphylococcus aureus ,Tissue Plasminogen Activator ,Drug Therapy, Combination ,Female ,Therapeutic Aspiration ,business ,Pleurodesis ,Fibrinolytic agent ,medicine.drug - Abstract
Background: Indwelling pleural catheters (IPC) are increasingly used for management of recurrent (especially malignant) effusions. Pleural infection associated with IPC use remains a concern. Intrapleural therapy with tissue plasminogen activator (tPA) and deoxyribonuclease (DNase) significantly reduces surgical referrals in non-IPC pleural infection, but data on its use in IPC-related pleural infection are scarce. Objective: To assess the safety and efficacy of intrapleural tPA and DNase in IPC-related pleural infection. Methods: Patients with IPC-related pleural infection who received intrapleural tPA/DNase in five Australian and UK centers were identified from prospective databases. Outcomes on feasibility of intrapleural tPA/DNase delivery, its efficacy and safety were recorded. Results: Thirty-nine IPC-related pleural infections (predominantly Staphylococcus aureus and gram-negative organisms) were treated in 38 patients; 87% had malignant effusions. In total, 195 doses (median 6 [IQR = 3–6]/patient) of tPA (2.5 mg–10 mg) and DNase (5 mg) were instilled. Most (94%) doses were delivered via IPCs using local protocols for non-IPC pleural infections. The mean volume of pleural fluid drained during the first 72 h of treatment was 3,073 (SD = 1,685) mL. Most (82%) patients were successfully treated and survived to hospital discharge without surgery; 7 required additional chest tubes or therapeutic aspiration. Three patients required thoracoscopic surgery. Pleurodesis developed post-infection in 23/32 of successfully treated patients. No major morbidity/mortality was associated with tPA/DNase. Four patients received blood transfusions; none had systemic or significant pleural bleeding. Conclusion: Treatment of IPC-related pleural infection with intrapleural tPA/DNase instillations via the IPC appears feasible and safe, usually without additional drainage procedures or surgery. Pleurodesis post-infection is common.
- Published
- 2021